Docket No. 293412US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Tiberio BRUZZESE

SERIAL NO: New US PCT Application based on PCT/EP05/00522

GAU:

FILED: Her

GALO.

FOR:

Herewith EXAMINER:

TREATMENT OF CENTRAL NERVOUS SYSTEM DISTURBANCES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

USE OF HIGHLY CONCENTRATED COMPOSITIONS OF SELECTED N-3 FATTY ACIDS FOR THE

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references cited in the International Search Report and listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- □ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Surinder Sachar

Registration No. 34,423

AP20 Rec'd PCT/PTO 21 JUL 2006

ATTY DOCKET NO. Form PTO 1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE 293412US0PCT based on PCT/EP05/00522 **APPLICANT** LIST OF REFERENCES CITED BY APPLICANT Tiberio BRUZZESE **FILING DATE GROUP** Herewith **U.S. PATENT DOCUMENTS EXAMINER** DOCUMENT SUB FILING DATE DATE NAME **CLASS** INITIAL NUMBER CLASS IF APPROPRIATE AA 6 331 568 12/18/01 HORROBIN, David Frederick ΑB 6 384 077 05/07/02 PEET, Malcolm et al. AC AD ΑE AF AG AΗ ΑI AJ ΑK AL AM AN **FOREIGN PATENT DOCUMENTS** DOCUMENT **TRANSLATION** DATE COUNTRY NUMBER YES NO 0 699 437 03//06/96 AO EP NO AΡ 0 599 576 06/01/94 EP NO AQ 0 347 056 12/20/89 EP NO AR AS AT ΑU ΑV OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) MELLOR, Jan E. et al.,"Omega-3 Fatty Acid Supplementation in Schizophrenic Patients", Human Psychopharmacology, Vol. AW 11, No.1, pgs. 39-46,1996. VREUGDENHIL, M et al.," Polyunsaturated fatty acids modulate sodium and calcium currents in CA 1neurons", National Academy of Science. Washington, US. Vol.93, No.22, pgs.12559-12563, 10-29-1996. AX VREUGDENHIL, M et al.," Anticonvulsant properties of polyunsaturated fatty acids", Society for Neuroscience, US, Vol.22, AY pgs. 2106, 1996. VOSKUYL, Rob A.," Is marine fat anti-epileptogenic?, Nutrition and Health ΑZ 2002, Vol.16, No.1, pgs. 51-53, 2002. Additional References sheet(s) attached Examiner **Date Considered** *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.